 The purpose of this study is to 1 evaluate pain-free efficacy of TreximetTM following treatment of menstrual migraine, 2 investigate levels of Calcitonin gene-related peptide CGRP, estrogen, cortisol, vasoactive intestinal peptide VIP, alpha a-amylase, Prostaglandin E2 PGE2, Prostaglandin I2 PGI2 and beta ß-endorphin in saliva before and after TreximetTM, 3 evaluate efficacy of TreximetTM to return to baseline levels following treatment, and 4 correlate estrogen in saliva vs. urinary estradiol at mid-luteal, onset of menstrually-related migraine, and after successful treatment with TreximetTM. 